Jefferson, Children’s Hospital Boston Researchers Show Another “Smart” Cancer Drug Can Have Toxic Effects on the Heart
(Published: 12-13-2007) Another FDA-approved targeted cancer drug, sunitinib (SutentTM, Pfizer), may be associated with cardiac toxicity, report researchers at Children’s Hospital Boston, Dana-Farber Cancer Institute
(Boston), and Thomas Jefferson University (Philadelphia). Their collaborative study, led by Ming Hui Chen, M.D., MMSc, a cardiologist
at Children’s who specializes in the cardiac health of cancer patients, appears in the December 15, 2007 issue of The Lancet, accompanied by an editorial.
Whipple Webcast at Jefferson Highlights Innovative Surgical Treatment for Pancreatic Cancer
(Published: 8-27-2007) Thomas Jefferson University Hospital will host a webcast featuring a mini-Whipple procedure (pylorus
preserving pancreaticoduodenectomy) used to treat pancreatic cancer. The webcast, which will feature an actual procedure and
panel discussion by the Jefferson Pancreatic Cancer and Related Diseases team, is scheduled for 4:30 p.m. ET on Tuesday, September
18, at www.JeffersonHospital.org/webcast.
New Jefferson Trial to Study Targeted Antiangiogenesis Drug Sutent™ and Radiation Against Cancer
(Published: 6-20-2007) Last year, the drug Sutent™ (sunitinib) made headlines for its effectiveness against kidney and gastrointestinal
cancers. Now, radiation oncologist at the Kimmel Cancer Center at Jefferson in Philadelphia are hoping to find out if combining
Sutent and radiation will help patients with a wide range of cancers.
News Archives:
New Chief Financial Officer Joins the Kimmel Cancer Center at Thomas Jefferson University
(Published: 10-9-2006) Richard W. Haldeman, MBA, has joined the Kimmel Cancer Center (KCC) at Thomas Jefferson University
in Philadelphia as its new Chief Financial Officer (CFO). In this new position, Mr. Haldeman will financially integrate the
research and clinical functions of the organization. He will also serve as lead financial representative for KCC director
Richard G. Pestell, M.D., Ph.D., in both of his roles as Vice President of Oncology Services at Thomas Jefferson University
Hospital and Associate Dean for Cancer Programs at Thomas Jefferson University.
Jefferson Scientists Show "Miracle" Cancer Drug Gleevec Can be Toxic to the Heart
(Published: 7-23-2006) Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets
in the cancer cell, can be dangerous to the heart. Not only that, but other similarly based drugs – called tyrosine kinase
inhibitors – could lead to heart problems as well, say researchers at the Center for Translational Medicine at Jefferson Medical
College in Philadelphia.
Procedure for Patients at Risk for Esophageal Cancer being Studied at Thomas Jefferson University Hospital
(Published: 5-19-2006) A new nonsurgical procedure for people who suffer from Barrett’s Esophagus is being studied at Thomas
Jefferson University Hospital in Philadelphia.
Jefferson Researchers Uncover Genetic Signature that Predicts Colon Cancer
(Published: 4-4-2006) Researchers at Jefferson Medical College in Philadelphia have uncovered a genetic “signature” that accurately
identifies colon cancer--a key, they hope, to better understand how the cancer develops.
Noted Georgetown Physician-Scientist Richard G. Pestell, M.D., Ph.D., Named Director of the Kimmel Cancer Center at Jefferson
(Published: 11-3-2005) Richard G. Pestell, M.D., Ph.D., an internationally renowned expert in oncology and endocrinology,
has been named director of the Kimmel Cancer Center at Jefferson in Philadelphia. The announcement was made today by Thomas
Jefferson University President Robert L. Barchi, M.D., Ph.D.
Thomas Jefferson University Hospital Honors Philanthropist Dorrance H. Hamilton and Past Jefferson Surgery Chair Francis E.
Rosato at 127th Anniversary Gala
(Published 9-26-2005) Thomas Jefferson University Hospital will honor surgeon Francis E. Rosato, M.D., and philanthropist
Dorrance H. “Dodo” Hamilton for their dedication to Jefferson at the hospital’s 127th anniversary gala.
Johns Hopkins Pancreas Specialist and Alimentary Tract Surgeon Joins Jefferson as Chair of Surgery
(Published: 9-12-2005) Preeminent pancreatic cancer surgeon Charles J. Yeo, M.D., has been selected as the new Samuel D. Gross
Professor and Chair of Surgery at Jefferson Medical College of Thomas Jefferson University and at Thomas Jefferson University
Hospital, Philadelphia.
“Pillcam” Enables Jefferson Physicians to Diagnose Diseases of Esophagus Without Using Endoscope
(Published: 6-8-2005) Most digestive disease specialists will tell you that patients would rather suffer from heartburn and
other diseases of the upper GI system than undergo a very effective but also potentially uncomfortable and relatively invasive
procedure to diagnose their problem.
Jefferson Radiation Oncologist Re-elected to Chair Prestigious Clinical Trials Group
(Published: 3-1-2005) Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College at
Thomas Jefferson University in Philadelphia and clinical director of Jefferson’s Kimmel Cancer Center, has been re-elected
to a third four-year term as Group Chair of the Radiation Therapy Oncology Group (RTOG), a Philadelphia-based federally funded
cancer clinical trials group that carries out multi-disciplinary research nationwide and in Canada.
Scott D. Goldstein M.D., Named Director of Colon and Rectal Surgery at Thomas Jefferson University Hospital
(Published: 5-13-2004) Colorectal surgeon Scott Goldstein, M.D., has been named director of Colon and Rectal Surgery, in the
Department of Surgery at Thomas Jefferson University Hospital, Philadelphia.
Jefferson's Bruce Boman, M.D., Ph.D., Elected President of Hereditary Colorectal Cancer Group
(Published: 3-23-2004) Bruce Boman, M.D., Ph.D, has been elected president of the Collaborative Group of the Americas on Inherited
Colorectal Cancer for the term 2003-2004.
